Dtsch Med Wochenschr 2012; 137(24): 1314-1316
DOI: 10.1055/s-0032-1305061
Kommentar | Commentary
Infektiologie, Pharmakotherapie
© Georg Thieme Verlag KG Stuttgart · New York

Antibiotika – quo vadit?

Antibiotics – quo vadit?
H. M. Lode
1   Institut für Klinische Pharmakologie und Toxikologie, Charité – Universitätsmedizin Berlin
,
R. Stahlmann
1   Institut für Klinische Pharmakologie und Toxikologie, Charité – Universitätsmedizin Berlin
› Author Affiliations
Further Information

Publication History

08 March 2012

03 May 2012

Publication Date:
05 June 2012 (online)

 
  • Literatur

  • 1 Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366: 485-487
  • 2 Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010; 51 (Suppl. 02) S183-S197
  • 3 Carlet J, Collignon P, Goldmann D et al. Society's failure to protect a precious resource: antibiotics. Lancet 2011; 378: 369-371
  • 4 Chisholm SA, Mouton JW, Lewis DA et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. J Antimicrob Chemother 2010; 65: 2141-2148
  • 5 Cuny C, Nathaus R, Layer F et al. Nasal colonization of humans with methicillin-resistant Staphylococcus aureus (MRSA) CC398 with and without exposure to pigs. PLoS One 2009; 4: e6800
  • 6 Domagk G. Ein Beitrag zur Chemotherapie bakterieller Infektionen. Dtsch Med Wochenschr 1935; 61: 250-253
  • 7 ECDC/EMEA Joint Technical Report 2009. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. EMEA/576176/2009.
  • 8 European Centre for Disease Prevention and Control. EARS-Net Database. http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx (letzter Zugriff 16. Mai 2012)
  • 9 Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N Engl J Med 2012; 366: 454-461
  • 10 Finch R. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother 2011; 66: 1945-1947
  • 11 Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Brit J Exp Pathol 1929; 10: 226-236
  • 12 Huttner B, Samore M. Outpatient antibiotic use in the United States: time to "get smarter". Clin Infect Dis 2011; 53: 640-643
  • 13 Johnson PD, Ballard SA, Grabsch EA et al. A sustained hospital outbreak of vancomycin-resistant Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203. J Infect Dis 2010; 202: 1278-1286
  • 14 Lewis HC, Mølbak K, Reese C et al. Pigs as source of methicillin-resistant Staphylococcus aureus CC398 infections in humans, Denmark. Emerg Infect Dis 2008; 14: 1383-1389
  • 15 Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66: 1941-1944
  • 16 Penicillin’s finder assays its future.. New York Times – June 26, 1945:21
  • 17 Piddock LJ. The crisis of no new antibiotics-what is the way forward?. Lancet Infect Dis 2012; 12: 249-253
  • 18 Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71-109
  • 19 Spellberg B, Blaser M, Guidos RJ et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52 (Suppl. 02) S397-S428
  • 20 Spellberg B. The antibiotic crisis: can we reverse 65 years of failed stewardship?. Arch Intern Med 2011; 171: 1080-1081
  • 21 van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient. Eur J Clin Microbiol Infect Dis 2011; 30: 603-610
  • 22 White AR. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J Antimicrob Chemother 2011; 66: 1948-1953